ES2098447T3 - Preparaciones farmaceuticas a base de matrices o revestimientos adherentes a la mucosa gastrointestinal. - Google Patents

Preparaciones farmaceuticas a base de matrices o revestimientos adherentes a la mucosa gastrointestinal.

Info

Publication number
ES2098447T3
ES2098447T3 ES92303357T ES92303357T ES2098447T3 ES 2098447 T3 ES2098447 T3 ES 2098447T3 ES 92303357 T ES92303357 T ES 92303357T ES 92303357 T ES92303357 T ES 92303357T ES 2098447 T3 ES2098447 T3 ES 2098447T3
Authority
ES
Spain
Prior art keywords
matrix
active ingredient
composition
matrices
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92303357T
Other languages
English (en)
Inventor
Yohko Akiyama
Shin-Ichiro Hirai
Naoki Nagahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2098447T3 publication Critical patent/ES2098447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE MUESTRA UNA COMPOSICION DE MATRIZ SOLIDA QUE ES SOLIDA A TEMPERATURA AMBIENTE, QUE COMPRENDE UN AGENTE VISCOGENICO, COMO UN POLIMERO DE ACIDO ACRILICO, CAPAZ DE DESARROLLAR VISCOSIDAD AL CONTACTO CON AGUA, DISPERSO AL MENOS EN LA CERCANIA DE LA CAPA SUPERFICIAL DE UNA PARTICULA DE MATRIZ QUE CONTIENE UN LIPIDO O UN ESTER DE ACIDO GRASO DE POLIGLICEROL Y UN INGREDIENTE ACTIVO. LA MATRIZ PUEDE SER TAL QUE LA PARTICULA DE MATRIZ QUE CONTIENE UN LIPIDO O UN ESTER DE ACIDO GRASO DE POLIGLICEROL Y UN INGREDIENTE ACTIVO HA SIDO REVESTIDA CON UNA COMPOSICION PROTECTORA QUE CONTIENE AL MENOS UN AGENTE VISCOGENICO. DICHA COMPOSICION PUEDE ADHERIRSE AL SISTEMA DIGESTIVO Y PERMANECER EN EL UN PERIODO PROLONGADO DE TIEMPO, AUMENTANDO ASI LA BIODISPONIBILDAD DEL INGREDIENTE ACTIVO. PREPARACIONES SOLIDAS, COMO GRANULOS Y GRANULOS FINOS, CONTIENEN LA COMPOSICION DE MATRIZ ANTERIOR.
ES92303357T 1991-04-19 1992-04-14 Preparaciones farmaceuticas a base de matrices o revestimientos adherentes a la mucosa gastrointestinal. Expired - Lifetime ES2098447T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11674591 1991-04-19
JP22515591 1991-08-09

Publications (1)

Publication Number Publication Date
ES2098447T3 true ES2098447T3 (es) 1997-05-01

Family

ID=26455015

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92303357T Expired - Lifetime ES2098447T3 (es) 1991-04-19 1992-04-14 Preparaciones farmaceuticas a base de matrices o revestimientos adherentes a la mucosa gastrointestinal.

Country Status (12)

Country Link
US (4) US5576025A (es)
EP (1) EP0514008B1 (es)
JP (4) JP3272029B2 (es)
KR (1) KR100217165B1 (es)
AT (1) ATE149348T1 (es)
CA (1) CA2066384C (es)
DE (1) DE69217711T2 (es)
DK (1) DK0514008T3 (es)
ES (1) ES2098447T3 (es)
GR (1) GR3023383T3 (es)
SG (1) SG50480A1 (es)
TW (1) TW209174B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114867363A (zh) * 2019-12-10 2022-08-05 比利时胶囊公司 含脂质基质核心和活性成分的颗粒

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
ES2145102T3 (es) * 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd Formulacion que comprende una sustancia antibacteriana y una sustancia antiulcerosa.
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19600324A1 (de) * 1996-01-08 1997-07-10 Basf Ag Granulate für kosmetische und pharmazeutische Zubereitungen
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
CA2253260A1 (en) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
KR20000076329A (ko) 1997-03-25 2000-12-26 다케다 야쿠힌 고교 가부시키가이샤 위장 점막 부착성 약제 조성물
AU6422798A (en) * 1997-03-25 1998-10-20 Takeda Chemical Industries Ltd. Stabilized urease inhibitor
EP1003476B1 (en) * 1997-08-11 2004-12-22 ALZA Corporation Prolonged release active agent dosage form adapted for gastric retention
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
WO1999010010A1 (fr) * 1997-08-27 1999-03-04 Takeda Chemical Industries, Ltd. Preparation orale a liberation prolongee
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
EA003512B1 (ru) 1998-03-20 2003-06-26 Кова Ко., Лтд. Желудочная и/или дуоденальная клейкая лекарственная форма
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
PT1183014E (pt) 1999-06-14 2003-12-31 Cosmo Spa Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
CN1162183C (zh) * 1999-08-09 2004-08-18 大日本制药株式会社 含有脱乙酰壳多糖粉末的固体制剂及其生产工艺
JP2001048809A (ja) * 1999-08-10 2001-02-20 Dainippon Pharmaceut Co Ltd ポリグリセリンベヘニン酸エステル含有徐放性坐剤
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
AU6730400A (en) 1999-08-26 2001-03-26 Takeda Chemical Industries Ltd. Matrix adhering to nasal mucosa
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
CN1312080A (zh) * 2000-02-18 2001-09-12 日本脏器制药株式会社 含有脂肪酸的组合物
JP4779192B2 (ja) * 2000-09-13 2011-09-28 大正製薬株式会社 溶出制御された製剤用粒子
HU230686B1 (en) 2000-10-30 2017-08-28 Euro Celtique Sa Controlled release hydrocodone compositions
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2380287T3 (es) * 2001-06-11 2012-05-10 Xenoport, Inc. Profármacos de análogos de GABA, composiciones y sus usos
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
ES2187380A1 (es) * 2001-11-16 2003-06-01 Sanchez Juan Balufo Mejoras introducidas en productos destinados al consumo humano o animal.
EP1585960A2 (en) * 2002-01-14 2005-10-19 Vertex Pharmaceuticals Incorporated Mucin immobilized chromatography
KR100937113B1 (ko) * 2002-01-16 2010-01-18 아스텔라스세이야쿠 가부시키가이샤 경구흡수 개선용 의약 조성물
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US7846478B2 (en) * 2002-01-31 2010-12-07 Henkel Ag & Co. Kgaa Bioadhesive composition
US8728510B1 (en) * 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
MXPA05003162A (es) * 2002-09-26 2005-07-05 Yamanouchi Pharma Co Ltd Agentes mejoradores de absorbibilidad de droga.
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2004096208A1 (en) * 2003-04-25 2004-11-11 Mitsubishi Pharma Corporation Composition for oral administration containing alkylene dioxybenzene derivative
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DE10332160A1 (de) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
KR100733028B1 (ko) * 2003-08-29 2007-06-28 사토 세이야쿠 가부시키가이샤 직장 투여용 제제
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
JP2007535545A (ja) * 2004-04-28 2007-12-06 プロキャリア・インコーポレーテッド 難吸収性薬剤の経口投与のための製剤
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
EP1750674A4 (en) * 2004-05-27 2012-05-23 Advanced Bionutrition Corp MICROPARTICLES FOR THE ORAL LEVY
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DE102004036437A1 (de) * 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
JP4787503B2 (ja) * 2005-01-12 2011-10-05 京セラケミカル株式会社 固形製剤の製造方法
JP4787507B2 (ja) * 2005-01-24 2011-10-05 京セラケミカル株式会社 固形製剤及びその製造方法
MX2007013327A (es) * 2005-04-25 2008-04-21 Teva Pharma Formulaciones de liberacion prolongada.
CA2521272A1 (en) * 2005-10-04 2007-04-04 Bernard Charles Sherman Capsules comprising topiramate
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US8460726B2 (en) * 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
US8080094B2 (en) * 2007-01-22 2011-12-20 Y2 Ultra-Filter, Inc. Electrically stimulated air filter apparatus
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
KR20100075599A (ko) * 2007-10-03 2010-07-02 아사히비루 가부시키가이샤 과립, 정제 및 이들의 제조 방법
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
EP2172203A1 (en) * 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
CN106987525B (zh) 2009-05-26 2020-10-27 先进生物营养公司 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法
CN102458370A (zh) 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
FR2955258A1 (fr) * 2010-01-20 2011-07-22 Biopharmex Holding Ltd Composition injectable
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
SG182317A1 (en) 2010-01-28 2012-08-30 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
EP2603100B1 (en) 2010-08-13 2018-04-25 Advanced BioNutrition Corp. Dry storage stabilizing composition for biological materials
ES2556985T3 (es) 2011-01-11 2016-01-21 Capsugel Belgium Nv Nuevas cápsulas duras que comprenden pululano
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US9636360B2 (en) * 2012-09-18 2017-05-02 pH Science Holdings, Inc Method and composition for treating gastro-esophageal disorders
JP6285413B2 (ja) * 2013-02-25 2018-02-28 テルモ株式会社 多糖粉末およびこれを含む癒着防止材
PL3188713T3 (pl) 2014-08-11 2020-11-02 Perora Gmbh Sposób wywoływania uczucia sytości
AU2015303210B2 (en) 2014-08-11 2018-11-08 Perora Gmbh Formulation comprising particles
EP3319593A1 (en) 2015-07-07 2018-05-16 perora GmbH Edible composition comprising a polysaccharide and a lipid
WO2017005890A1 (en) 2015-07-07 2017-01-12 Perora Gmbh Method of inducing satiety
WO2017019273A1 (en) 2015-07-29 2017-02-02 Advanced Bionutrition Corporation Stable dry probiotic compositions for special dietary uses
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
BR112019021391A2 (pt) 2017-04-14 2020-05-05 Capsugel Belgium Nv cápsulas de pululano
EP3610028A1 (en) 2017-04-14 2020-02-19 Capsugel Belgium NV Process for making pullulan
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
JP7260913B2 (ja) 2017-06-27 2023-04-19 株式会社バイオセレンタック 粘膜付着性経口製剤
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
JP7376582B2 (ja) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー 成形体への圧縮を目的とした粉末材料用添加剤
EP3870229A1 (de) * 2018-10-22 2021-09-01 IOI Oleo GmbH Additiv für ein zur verpressung zu formkörpern vorgesehenes pulver
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922339A (en) * 1974-06-20 1975-11-25 Kv Pharm Co Sustained release medicant
CH627449A5 (de) * 1977-03-25 1982-01-15 Hoffmann La Roche Verfahren zur herstellung von mikrokristallinem vitamin a-acetat, sowie von trockenen, frei-fliessenden praeparaten, in welchen vitamin a-acetat in mikrokristalliner form vorliegt.
JPS6042766B2 (ja) 1978-12-09 1985-09-25 日本化薬株式会社 基剤
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
FR2485370A1 (fr) * 1980-06-30 1981-12-31 Commissariat Energie Atomique Support inerte en copolymere reticule, son procede de preparation et son utilisation pour la realisation de medicaments retard
JPS6029682B2 (ja) 1980-07-11 1985-07-12 山之内製薬株式会社 苦味のない製剤用組成物およびその製造法
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
US4664915A (en) * 1981-07-01 1987-05-12 Bristol-Myers Company Compressed and formed alkaline component suitable for use in buffered aspirin product
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS61148115A (ja) 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
JPS63101332A (ja) 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
DE3702029A1 (de) * 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JP2526965B2 (ja) 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
EP0407464A1 (en) * 1988-04-19 1991-01-16 Southwest Research Institute Controlled release of active ingredients from capsules having a salt sensitive shell material
JP2759972B2 (ja) 1988-08-05 1998-05-28 富士通株式会社 セグメント顕示処理方法
AU645003B2 (en) 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
JPH02193914A (ja) 1989-01-23 1990-07-31 Sumitomo Pharmaceut Co Ltd マトリックス型持続性製剤
JPH0720865B2 (ja) 1989-02-10 1995-03-08 武田薬品工業株式会社 抗菌剤
ES2066120T3 (es) 1989-02-10 1995-03-01 Takeda Chemical Industries Ltd Uso de derivados de bencimidazol como agentes antibacterianos.
JPH0338247A (ja) 1989-07-06 1991-02-19 Nippon Kasei Kk 脱臭剤
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
IE65045B1 (en) 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114867363A (zh) * 2019-12-10 2022-08-05 比利时胶囊公司 含脂质基质核心和活性成分的颗粒

Also Published As

Publication number Publication date
SG50480A1 (en) 1998-07-20
ATE149348T1 (de) 1997-03-15
KR100217165B1 (ko) 1999-09-01
US5576025A (en) 1996-11-19
US5731006A (en) 1998-03-24
JPH05132416A (ja) 1993-05-28
JP2007246547A (ja) 2007-09-27
DK0514008T3 (da) 1997-05-12
EP0514008A1 (en) 1992-11-19
CA2066384C (en) 2007-04-03
JP2001354593A (ja) 2001-12-25
EP0514008B1 (en) 1997-03-05
CA2066384A1 (en) 1992-10-20
DE69217711D1 (de) 1997-04-10
KR920019336A (ko) 1992-11-19
JP4084000B2 (ja) 2008-04-30
JP2001354550A (ja) 2001-12-25
DE69217711T2 (de) 1997-07-17
TW209174B (es) 1993-07-11
US20020142041A1 (en) 2002-10-03
US6368635B1 (en) 2002-04-09
JP3272029B2 (ja) 2002-04-08
GR3023383T3 (en) 1997-08-29

Similar Documents

Publication Publication Date Title
ES2098447T3 (es) Preparaciones farmaceuticas a base de matrices o revestimientos adherentes a la mucosa gastrointestinal.
DE69022876T2 (de) Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
NO20033653D0 (no) Ny filmcoating
MX167794B (es) Particulas de perfume revestidas
KR870010865A (ko) 피복된 복용 형태
DE69302107T2 (de) Durch Wasser inaktivierbarer, druckempfindlicher Klebstoff
DE59812646D1 (de) Laminare Arzneiform
ATE166574T1 (de) Pflaster zur transdermalen applikation mit einem wirkstoffhaltigem polymerfilm
EP1248150A3 (en) Radiation sensitive material and method for forming pattern
DE69020875D1 (de) Oestrogenhaltiges Gelpräparat.
ATE170745T1 (de) Kapsel mit langzeitwirkung fuer die adhäsion im gastrointestinaltrakt
FR2514261B1 (fr) Nouvelle composition pour l'enrobage des aliments et des medicaments et granules ainsi enrobes
AU1125283A (en) Pharmaceutical in the form of a polyacrylate film
EP1291713A3 (en) Thermally developable imaging materials containing hydroxy-containing polymeric barrier layer
DE69214333T2 (de) Arzneizubereitung mit hohem Gehalt an Ibuprofenlysinat
JPS5742619A (en) Adhesive tape pharmaceutical
SE8600377D0 (sv) Belagda doseringsformer
JPS57176908A (en) Remedial adhesive tape or sheet
JPS57183714A (en) Medicinal pharmaceutical
JPS57128742A (en) Antifouling and algae-proofing polyester resin composition
WO1992019209A3 (en) Taste-masked medicaments and their preparation
JPS56138114A (en) Adhesive tape or sheet for treatment

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514008

Country of ref document: ES